Informationen:
Fehler:
ID
14957
Beschreibung
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01520389
Link
https://clinicaltrials.gov/show/NCT01520389
Stichworte
Versionen (1)
- 09.05.16 09.05.16 -
Hochgeladen am
9. Mai 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Advanced Solid Tumors NCT01520389
Eligibility Advanced Solid Tumors NCT01520389
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Advanced Solid Tumors NCT01520389
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
solid tumor
Item
patients must have histologically or cytologically confirmed advanced malignant solid tumor that has recurred or progressed following standard therapy, or that has not responded to standard therapy, or for which there is no standard therapy, or who are not candidates for standard therapy
boolean
C0280100 (UMLS CUI [1])
age
Item
patients must be > 18 years of age
boolean
C0001779 (UMLS CUI [1])
informed consent
Item
patients of their legal representatives must be able to understand and sign an informed consent form
boolean
C0021430 (UMLS CUI [1])
measurable tumor
Item
patients must have evaluable or measurable tumor(s)
boolean
C1302351 (UMLS CUI [1])
patients must be recovered
Item
patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy. up to ctcae grade 1 is acceptable for patients with known peripheral neuropathy
boolean
C2004454 (UMLS CUI [1])
abstain from sexual intercourse or to use an effective form of contraception
Item
women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of mm-151 (an effective form of contraception is an oral contraceptive or a double barrier method)
boolean
C1171321 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
curative antineoplastic therapy
Item
patients for whom potentially curative antineoplastic therapy is available
boolean
C2346834 (UMLS CUI [1,1])
C1273390 (UMLS CUI [1,2])
C1273390 (UMLS CUI [1,2])
pregnant or lactating
Item
patients who are pregnant or lactating
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0006147 (UMLS CUI [1,2])
active infection
Item
patients with an active infection or with an unexplained fever > 38.5°c during screening visits or on the first scheduled day of dosing. (at the discretion of the investigator, patients with tumor fever may be enrolled.)
boolean
C0009450 (UMLS CUI [1])
cns malignancies
Item
patients with untreated and/or symptomatic cns malignancies (primary or metastatic); patients with cns metastases who have undergone surgery or radiotherapy, whose disease is stable, and who have been on a stable dose of corticosteroids for at least 2 weeks prior to the first scheduled day of dosing will be eligible for the trial
boolean
C0348374 (UMLS CUI [1])